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Introduction
• Alzheimer’s Disease (AD) and Osteoporosis are common degenerative diseases of aging. Previous
research has found that AD and osteoporosis may overlap [4].
• Observational studies demonstrate a correlation between the osteoporosis and AD that suggest, rather
than one condition causing the other, both conditions are related by a common underlying mechanism
[4].
• Previous studies have investigated bone mass in mouse models that recapitulate the pathology of AD [4].
• This study focuses on the 5xFAD mouse model, another AD mouse model that exhibits a more
aggressive form of AD. Thus, the 5xFAD mouse model rapidly recapitulates major features of AD
amyloid pathway: rapidly accumulating Aβ42 in the brain, early amyloid deposition and gliosis, robust
intraneuronal Aβ labeling, neurodegeneration and neuron loss.
• The goal of this study was to investigate the skeleton of the 5xFAD mice and compare its bone density to
age-matched healthy control mice.
Abstract
Alzheimer’s Disease (AD) and Osteoporosis are common degenerative diseases of aging. AD has been considered a risk for osteoporosis and previous studies have shown that patients with AD have an increased risk for hip
fractures which are the result of osteoporosis, suggesting a link between reduced bone mass and AD. This experiment studied the 5xFAD mouse model which recapitulates many AD-related phenotypes. The objective was to
compare the bone mass of 5xFAD mice with AD-like phenotypes to mice without AD. The results demonstrate that 5xFAD mice have a progressive loss of bone mass as they age. Although previous papers have denoted similar
results in another AD mouse model, Tg2576, this is the first time these results were shown in the 5xFAD mouse model. As each mouse model of AD recapitulates a different aspect of the disease, these findings can help narrow
down what connects osteoporosis and AD. The findings confirm that AD mice have significantly reduced bone mass, consistent with the development of osteoporosis. The substantial change in bone mass over time between the
5xFAD mice and Wild-Type mice suggests that the disease’s effects are age-dependent.
Methodology 
5xFAD and Wild-Type (Control) Mice Tissues
The 5xFAD mouse model is a validated model of familial Alzheimer’s disease.
Micro-Computed Tomography (µCT)
The right femur of the wild-type (control) mice and 5xFAD mice were scanned and analyzed using µCT. 
Trabecular bone architecture was measured in a proximal region. Primary trabecular parameters included 
bone volume per total volume (BV/TV). Cortical geometry was measured in a 100 slice region at the 
midshaft at 50% of the total length of the femur. Primary cortical parameter includes cortical area (mm2).  
Bone Histological Analysis:
After µCT scanning, the bones were prepared for histological investigation by dehydration and 
decalcification of the femoral tissues. After all the calcium from bones were removed, samples were 
embedded in paraffin, cut into sections and mounted for tartrate-resistant acid phosphatase (TRAP) and 
Sudan Black B staining. 
Conclusions and Future Work
• We are currently performing TRAP staining, which is a method to identify active osteoclasts. 
• Considering other mouse models that recapitulate AD exhibit similar effects in trabecular and cortical bone, our current model could share the same mechanisms and pathologies that are driving the effects seen in those 
mouse models. Future work is necessary to identify the role of Aβ and RANKL Pathway  in the 5xFAD model. 
• We are also performing Sudan Black staining to investigate senescence, a process known to occur in the brains of AD patients, to understand whether the bone resorption is due to cellular aging.	
• Bone loss has not been studied nor published before in the 5xFAD model. Although AD and osteoporosis are not commonly considered linked diseases, past research presents compelling information that they are 
interconnected. Continuing to investigate the AD mouse models to is crucial to further our understanding of these two devastating diseases of aging.
Figure 1: X-ray scan of the Femurs. The 
left image displays an X-ray of a Wild-
Type mice femur. The right image displays 
an X-ray of a 5xFAD transgenic mice 
femur. 
Figure 2: 3D Reconstruction of µCT
Scanned Trabecular Bone.
Figure 3: Trabecular Bone Volume per 
Total Volume (BV/TV) Comparison.
Figure 4 Trabecular Bone Volume per Total
Volume (BV/TV) Comparison.
Figure 5: Cortical Area of Femur Bone
Figure 6: Cortical Area of Femur Bone
Figure 7: Tartrate Resistant Acid 
Phosphatase (TRAP) Staining for 
Osteoclasts.
Figure 8: Sudan Black B 
(SBB) senescence Staining.
Findings
• The data suggest that 
5xFAD mouse model 
recapitulates the low bone 
mass characteristics of 
osteoporosis
• The change in bone density 
over time observed in the 
5xFAD mice suggest that 
the bone mass loss is 
progressive
• The data and images 
collected from the study 
provide evidence to suggest 
that the combination of 
mutations in the diseased 
5xFAD mice have an effect 
on the bone resorption of 
the trabecular bone in the 
5xFAD mice in comparison 
to the WT mice (Figure 
1,4).
• Male 5xFAD mice do not 
experience cortical bone 
resorption to the same 
extent observed in female 
mice (Figure 5, 6).
Cortical Bone
µCT analyses show that over 
time male 5xFAD mice do 
not have a decreased cortical 
bone are in comparison with 
WT mice. Older female 
mice exhibit a lower cortical 
bone area than WT mice. 
Trabecular Bone
Male 5xFAD mice exhibit a decrease
in trabecular bone density over time
in contrast to Wild-Type (WT) mice
(Figure 3). Older female 5xFAD mice
exhibit a lower trabecular bone
density than the WT mice.
